<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="27131">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02753530</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY00002461</org_study_id>
    <secondary_id>R01FD004809-01A2</secondary_id>
    <nct_id>NCT02753530</nct_id>
  </id_info>
  <brief_title>Study of Arimoclomol in Inclusion Body Myositis (IBM)</brief_title>
  <official_title>Phase II Study of Arimoclomol for the Treatment of Sporadic Inclusion Body Myositis (IBM)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Kansas Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Kansas Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Funding Source - FDA OOPD. The purpose of this study is to evaluate the safety and efficacy
      of the study drug, Arimoclomol in IBM patients.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2017</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Investigator</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Decline in Inclusion body myositis functional rating scale (IBMFRS)</measure>
    <time_frame>Change from Baseline to Month 12</time_frame>
    <description>Measured by rate of decline in the IBMFRS between experimental and placebo groups. The IBMFRS is a 10 item questionnaire. Scores for each item range from 0 to 4. There is a total maximum score of 40 and minimum score of 0. The higher the score the better functional status of the person.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Manual Muscle Testing (MMT)</measure>
    <time_frame>Change from Baseline to Month 20</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum voluntary isometric contraction (MVICT) of quadriceps</measure>
    <time_frame>Change from Baseline to Month 20</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Grip and pinch test</measure>
    <time_frame>Change from Baseline to Month 20</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>modified timed up and go (mTUG)</measure>
    <time_frame>Change from Baseline to Month 20</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6 minute walk test with 2 minute distance captured</measure>
    <time_frame>Change from Baseline to Month 20</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health Assessment Questionnaire (HAQ-DI)</measure>
    <time_frame>Change from Baseline to Month 20</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SF-36</measure>
    <time_frame>Change from Baseline to Month 20</time_frame>
    <description>Measured using the Short form health survey with 36 items (SF-36).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Count of adverse events</measure>
    <time_frame>Change from Baseline to Month 20</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Decline in Inclusion body myositis functional rating scale (IBMFRS)</measure>
    <time_frame>Change from Baseline to Month 20</time_frame>
    <description>Measured by rate of decline in the IBMFRS between experimental and placebo groups. The IBMFRS is a 10 item questionnaire. Scores for each item range from 0 to 4. There is a total maximum score of 40 and minimum score of 0. The higher the score the better functional status of the person.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Inclusion Body Myositis</condition>
  <arm_group>
    <arm_group_label>Arimoclomol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be asked to take 400mg arimoclomol three times a day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will be asked to take 400mg placebo three times a day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Arimoclomol</intervention_name>
    <description>2 200mg pills taken 3 times per day during breakfast, early afternoon and at bedtime</description>
    <arm_group_label>Arimoclomol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>2 matched placebo pills to be taken 3 times per day during breakfast, early afternoon and at bedtime</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Meet any of the European Neuromuscular Centre Inclusion Body Myositis research
             diagnostic criteria 2011 categories for IBM

          -  Demonstrate being able to arise from a chair without support from another person or
             device

          -  Able to ambulate at least 20 ft/6 meters with or without assistive device. Once
             arisen from the chair, participant may use any walking device, i.e. walker/frame,
             can, crutches, or braces. They cannot be supported by another person and cannot use
             furniture or wall for support.

          -  Body weight of &gt;= 40 kg

          -  Pre-menopausal women must have a negative pregnancy tst prior to dosing iwht study
             medication.

          -  If a participant in the bimagrumab study, the participant must be off of the study
             medication for at least 6 months.

          -  Able to give informed consent

        Exclusion Criteria:

          -  History of any of the following excludes subject participation in the study: chronic
             infection particularly HIV or Hepatitis B or C; cancer other than basal cell cancer
             less than five years prior; or other chronic serious medical illnesses.

          -  Presence of any of the following on routine blood screening: WEB &lt;3000; platelets &lt;
             100,000; hematocrit , 30%; BUN &gt; 30 mg%; creatinine &gt; 1.5 mg%; symptomatic liver
             disease with serum albumin &lt; 3 g/dL.

          -  History of most recent cratine kinase &gt;15x the upper limit of normal without any
             other explanation besides IBM.

          -  History of non-compliance with other therapies

          -  Use of testosterone except for physiologic replacement doses in case of androgen
             deficiency. Participants must have documented proof of the androgen deficiency.

          -  Coexistence of other disease that would be likely to affect outcome measures.

          -  Drug or alcohol abuse within past three months

          -  Participation in a recent drug study in the last 30 days prior to the screening visit
             or use of a biologic agent less than 6 months prior to the screening visit.

          -  Women who are lactating or unwilling to use adequate method of birth control who are
             not surgically sterile. Adequate birth control includes use of intrauterine device,
             abstinence, or oral contraceptives or a double barrier method, e.g condom plas
             diaphragm will be necessary for both male and female participants.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mazen Dimahckie, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Kansas Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Laura Herbelin</last_name>
    <phone>(913) 588-5095</phone>
    <email>LHERBELIN@kumc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Mazen Dimachkie, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of College of London</name>
      <address>
        <city>London</city>
        <zip>WC1N 3BG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Iwona Skorupinska, BSc, RGN</last_name>
      <phone>0203-108-7515</phone>
      <email>iwona.skorupinska@uclh.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Michael Hanna, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pedro Machado, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 5, 2017</lastchanged_date>
  <firstreceived_date>April 25, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Kansas Medical Center</investigator_affiliation>
    <investigator_full_name>Mazen Dimachkie, MD</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Myositis</mesh_term>
    <mesh_term>Myositis, Inclusion Body</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
